Tiziana Life Sciences PLC (LON:TILS – Get Free Report)’s stock price was up 8.3% during trading on Friday . The stock traded as high as GBX 59 ($0.74) and last traded at GBX 58.50 ($0.74). Approximately 297,127 shares changed hands during mid-day trading, a decline of 43% from the average daily volume of 522,223 shares. The stock had previously closed at GBX 54 ($0.68).
Tiziana Life Sciences Price Performance
The company has a current ratio of 6.54, a quick ratio of 6.41 and a debt-to-equity ratio of 2.36. The firm’s 50-day moving average price is GBX 58.50 and its two-hundred day moving average price is GBX 58.50. The stock has a market cap of £113.85 million and a PE ratio of -3.59.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.
Further Reading
- Five stocks we like better than Tiziana Life Sciences
- What Are Growth Stocks and Investing in Them
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- The 3 Best Retail Stocks to Shop for in August
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Stock Dividend Cuts Happen Are You Ready?
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.